Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × BCG Vaccine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20 Non-Muscle Invasive Bladder Neoplasms 9 Colorectal Neoplasms 3 Colonic Neoplasms 3 Neoplasms 2 Lung Neoplasms 2 Side Effect of Drug 1 Sarcoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligospermia 1 Neuroblastoma 1 Melanoma 1 Fibrosis 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 132 Dexamethasone 106 Rituximab 70 fludarabine 64 Cytarabine 58 Lenalidomide 55 Gemcitabine 54 fludarabine phosphate 48 Bortezomib 47 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 41 Cisplatin 40 Peripheral Blood Stem Cell Transplantation 37 Filgrastim 37 pomalidomide 36 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 30 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Temozolomide 24 Nivolumab 24 Mycophenolic Acid 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05037279 2025-02-20

EVER

Verity Pharmaceuticals Inc.

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡